Teva Fails On Quillivant XR Appeal – Five Years After Winning
Remanded 2020 District Court Decision Affirmed On Appeal
Teva’s Actavis looks unlikely to be launching its proposed generic version of Tris Pharma’s Quillivant XR (methylphenidate) extended-release oral suspension soon, after a remanded district court decision that went against the firm was upheld on appeal.
You may also be interested in...
Teva Fails To Sidestep Eight Of Nine QuilliChew ER Patent Claims
A proposed Teva Pharmaceutical generic would infringe on multiple patents for Tris Pharma’s QuilliChew ER, a New Jersey district court has ruled.
Teva Falls Short On Challenge To Velphoro Formulation Patent
Teva has been shot down in its attempts to circumvent a key US patent shielding Vifor Pharma’s Velphoro dialysis drug.
Actavis Quillivant XR finding is overturned
Actavis has suffered a setback in its attempts to bring a generic of Tris Pharma’s Quillivant XR (methylphenidate) extended-release suspension to market ahead of patent expiry, after a US Court of Appeals vacated and remanded a favourable district court ruling on numerous patent claims due to “inadequate fact-findings”.